A Phase II Study to Assess the Activity of TroVax (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVA 5T4 (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms TRIOC

05 Aug 2024 Results assessing the effectiveness and safety of MVA-5T4 as treatment for asymptomatic relapsed ovarian cancer published in the International Journal of Gynecological Cancer
21 Sep 2020 Primary endpoint (Progression Rate) has not been met, according to results presented at the 45th European Society for Medical Oncology Congress.
21 Sep 2020 After an unforeseen interim trial suspension led to limited drug supply, so trial later changed to a single arm study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com